GlassScriptPhysician profile
Gary Lee Berebitsky
NPI 1740223114
$787.63
in general payments reported to CMS, 2019-2025
14 companies · $69.49 in 2025
The $69.49 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.86 · 2020: $29.88 · 2021: $154 · 2022: $165 · 2023: $200 · 2024: $70.28 · 2025: $69.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $161.59 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $130.88 | 2019-2025 | Bexsero, Pediarix |
| Pfizer INC. | $113.88 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $64.46 | 2021-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $52.87 | 2021-2022 | |
| Sanofi Pasteur INC. | $42.05 | 2019-2023 | |
| Kaleo, INC. | $39.97 | 2022 | |
| Supernus Pharmaceuticals, INC. | $33.41 | 2022 | |
| Sobi, INC | $30.92 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $30.73 | 2022-2023 | Flumist Quadrivalent |
| Krystal Biotech INC | $30.40 | 2023 | Vyjuvek |
| Sarepta Therapeutics, INC. | $24.72 | 2019 | |
| Phadia US INC. | $17.40 | 2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $14.35 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Berebitsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.